Lyme disease is an emerging infection that has now become the most commonly reported vectorborne disease in the United States. In the 20 years since its initial description, scientific and technological advances have led to candidate vaccines for the prevention of Lyme disease. Recombinant outer surface protein A (OspA) vaccines have been successful in protecting mice in tick-challenge experiments. A candidate OspA vaccine has been found to be safe and immunogenic in phase I and II studies. This article describes some of the lessons that were learned and some of the unique obstacles encountered in the design and implementation of a large phase III efficacy field trial. Pivotal trials of vaccines for Lyme disease can be a major investment of time and resources for subjects, investigators, and sponsors. If properly conducted, they also present unique opportunities to expand our knowledge of the disease.
In January 1995, SmithKline Beecham Pharmaceuticals initioccur weeks to years following infection, may cause complex rheumatologic, neurological, and cardiac manifestations [5] . ated a prospective phase III multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, These variable manifestations can make definitive diagnosis problematic and present difficulties in determining case definiand immunogenicity of a lipoprotein -outer surface protein A (OspA) vaccine for prevention of Lyme disease (LD). Initiating tions for use in vaccine efficacy trials. The long latency period for the appearance of symptoms also has implications for a this pivotal trial presented a formidable challenge because of a large number of issues not usually encountered in vaccine trial, since prolonged surveillance must be employed. trials. In this article we discuss the lessons and unique obstacles encountered in undertaking such a venture and the steps taken to address these issues.
Vaccine Development
Recombinant DNA technology was used to express the OspA Background of B. burgdorferi (ZS7 strain) in lipidated form for use as an antigen in a vaccine for the prevention of LD. The ZS7 strain LD is an emerging infection with growing public health belongs to the genospecies B. burgdorferi sensu strictu, as do consequences in parts of the United States and Europe [1] . LD virtually all eastern North American strains of the agent of was first recognized as a distinct clinical entity in 1975, followLyme disease. Preclinical studies showed that this vaccine, ing investigation near Lyme, Connecticut, of a cluster of cases adsorbed onto aluminum hydroxide, was able to protect originally thought to be juvenile rheumatoid arthritis [2] . Bor-C3H/HeJ mice when challenged by naturally infected ticks relia burgdorferi was subsequently identified as the causative collected from the northeastern United States, an area where organism and is now known to be transmitted by the bite of LD is intensely endemic [6] . an infected Ixodes tick. OspA, a 31-kD protein, is a major
In small animals, minimal protective antibody titers have surface protein of the spirochete [3] and has been identified as been documented [7] . The protection conferred by the vaccine a promising vaccine candidate [4] . may occur through two complementary mechanisms. CirculatSince the original description of the disease in 1975, the ing antibodies to OspA are produced that are capable of neuprotean clinical manifestations of LD have been well described tralizing spirochetes within the tick mid-gut, even before transand characterized. In the United States, the first recognized mission [4, 8] ; they may also kill the organisms directly in sign is usually erythema migrans, a characteristic expanding the host [4] . Tick transmission studies have also indicated a annular rash with central clearing that occurs at the site of the significant degree of vaccine-induced cross-protection between tick bite in Ç60% -80% of cases. Late-stage disease, which can spirochetes from different regions of the U.S. [9] . Following the initial phase I studies, a double-blind, placebocontrolled dose-range study was conducted in 350 healthy adult residents of three New England islands on which LD is highly vations: all doses were well tolerated, although mild local reac-10 states were selected for the pivotal trial. The distribution by geographic area was as follows: New England states (Contions (mostly soreness at the injection site, in 40% -85%) were common [11] .
necticut, Rhode Island, Massachusetts, and Maine) accounted for 19 sites and 60% of the study population; Mid-Atlantic These early studies not only provided important clinical and laboratory data but also were valuable learning experiences states (New York, Pennsylvania, New Jersey, Delaware, and Maryland) accounted for 11 sites and 39% of the study populawith regard to issues such as determination of case definition and documentation of infection. They also provided encouragtion; and 1 site in the Midwest (Wisconsin) accounted for 1% of the study population. ing signs for the concept of an efficacious vaccine and reinforced the notion that a very large field trial would be necessary
In addition to affecting site selection, the variation in reported rate and the estimation of the true incidence of the to prove efficacy. disease made it difficult to determine the appropriate sample size. With reported seasonal attack rates that vary in most Epidemiological Data publications from 0.1% to 4.0%, the sample size required to detect vaccine efficacy would vary significantly. It was decided As in most vaccine trials, identifying the population at risk is a critical component. As far as LD is concerned, defining to base the sample size and power calculations on a conservative estimate of an LD seasonal attack rate of 0.5%. this population is particularly challenging because of several factors, including considerable variation in attack rates, even Eight thousand subjects (4,000 per group) would provide ample power for the primary endpoint analysis. While this within areas of endemicity; seasonal transmission; year-to-year variability in incidence; and the need for outdoor exposure by number of subjects should provide reasonably tight confidence intervals, it will not be sufficient to determine vaccine efficacy subjects.
LD has rapidly become the most commonly reported vectoragainst rare manifestations of LD with comfortable precision. The cost and feasibility of conducting a trial involving a huge borne disease in the United States [12] . Surveillance for LD was initiated by the Centers for Disease Control and Prevention number of subjects must be balanced against the potential statistical shortcomings. (CDC) in 1982. Since that time there has been at least a 19-fold increase in reported cases. The reason for this dramatic increase is multifactorial and includes increased awareness by Timing of Vaccinations health care providers, increased contact between humans and deer ticks, and improved reporting of cases since LD became
The complex enzootic cycle of B. burgdorferi has been well defined and accounts for the seasonal occurrence of LD [17] . a reportable condition in the United States in 1991.
Although the true incidence of LD in the United States is This has implications for studying the disease, since the logistics of timing the vaccinations for all the enrollees must be unknown, the overall reported incidence rate was 5.2 per 100,000 for 1994. Eight states reported greater rates per addressed and decisions regarding the number of tick seasons to be evaluated must be made. With ú10,000 subjects enrolled, 100,000: Connecticut, 62.2; Rhode Island, 47.2; New York, 29.2; New Jersey, 19.6; Delaware, 15.5; Pennsylvania, 11.9; it was decided that two tick seasons would provide a comfortable amount of safety data and sufficient exposure to assess Wisconsin, 8.4; and Maryland, 8.3. The cases in these states accounted for 11,476 (88%) of the cases reported nationally the vaccine efficacy following primary immunization with 2 doses 1 month apart, as well as following a booster dose admin- [13] . These figures are strikingly higher than those for 1993. Evidence of seasonal variation has been well documented. In istered 1 year later. Prolonged surveillance was employed because of the long latency period for the appearance of some 1993, a total of 8,285 cases of LD were reported to the CDC by 44 states, 15% less than the number of LD cases (9, 677) of the symptoms (e.g., rheumatological and neurological manifestations) and because it will assist in addressing the issue of reported in the continental United States during 1992 [14] .
There is considerable variation even within areas of endemicwhether vaccination alters or attenuates the disease process.
To potentially be protected against B. burgdorferi infection, ity. In 1992, Connecticut had a statewide incidence of 53 cases/ 100,000, with some communities reporting rates exceeding 250 subjects must have developed the minimal protective antibody titer as predicted by the preclinical studies. The phase II studies cases/100,000 [15] . In a prospective cohort study conducted in one Connecticut county, clinical and asymptomatic B. burgrevealed that 4 weeks after the second dose of 30 mg of the lipoprotein-OspA vaccine, this level of antibody was easily dorferi infection in schoolage children was evaluated during three tick seasons (1990 -1992) . The incidences of clinical LD achieved. Therefore, subjects received two doses of vaccine 4 weeks prior to the earliest potential exposure period. This tight and asymptomatic B. burgdoferi infection were 10.1 and 3.8 cases/1,000 person-years, respectively [16] .
timetable presents a major constraint on LD vaccine efficacy trials. The high incidence in some areas facilitated selection of sites. However, in order to obtain a representative cross-section
In the northeastern United States, Ixodes scapularis, the deer tick, feeds on humans from April/May through September/ of affected geographic areas, study sites in communities with lower incidence rates were chosen as well. Thirty-one sites in October. Consequently, the vaccinations had to be initiated in S73 CID 1997;25 (Suppl 1) Implementation of Lyme Vaccine Trial late January to early February, followed by the second dosage and symptoms. LD presents special problems since the clinical manifestations are protean, and laboratory testing is problemin late February to early March, in order to have potentially protective titers established by April/May. This translated into atic as well. Cultures, PCR, and determinations of T cellmediated responses provide evidence of B. burgdorferi infecvaccinating ú10,000 subjects in a 4 -6-week window twice in a period of 3 months. Educating, coordinating, and monitoring tion but are not routinely available options except in some research laboratories. ELISAs are commercially available but such an undertaking required a tremendous effort on the part of study and site personnel and represented a potential drain lack sufficient sensitivity and specificity for use in efficacy trials. Western blot (WB) assays are specific but need standardon resources. The 98.8% rate of compliance for subjects receiving both doses is a tribute to the efforts at each site.
ization. Since no single laboratory or clinical parameter can be utiAnother issue regarding timing of vaccination, which was not initially appreciated, was the potential exposure of vaccine lized to identify all suspected cases, criteria have been developed by the CDC. The CDC criteria, however, were developed to extreme temperatures during shipping in January and February. This was addressed by insulating the shipping containers as a surveillance tool, which frequently necessitates a compromise between sensitivity and specificity to reach the optimal to avoid freezing and attaching a thermal recording device to each shipment package.
surveillance objective. For example, cases of LD presenting as a flulike illness or involving asymptomatic seroconversion are not included in the CDC definition.
Enrollees
All these subsets must be captured in an efficacy trial. The CDC criteria were therefore deemed to be inadequate for the Vaccine trials usually require that subjects be in good health and be compliant with the protocol procedures. Trials involving purpose of conducting a pivotal efficacy trial. The final protocol case definition included several clinical and serological subsets, LD also require that subjects have potential exposure to ticks. Outdoor exposure such as biking or hiking was emphasized in with the primary analysis being dependent upon objective evidence of infection. advertisements for potential subjects in order to obtain enrollees with maximal potential tick exposure. Regional and local adAnother case definition issue that arose during the phase II study was the criteria for WB positivity. The CDC/Association vertising through all available media venues in the community was implemented very actively by individual investigators and of State and Territorial Public Health Laboratory Directors Working Group criteria for defining WB positivity [18] were by the sponsor. Investigators were also offered an incentive for surpassing enrollment milestones, which further stimulated incorporated into the phase III protocol along with a definition of seroconversion. Indeed, one significant advantage of a proactive recruitment.
Remaining in an area of endemicity for at least 1 month spective trial is that both prestudy and poststudy sera can be available for testing. during the LD transmission season was incorporated as an inclusion criterion for subjects to be considered for the per-
The protocol case definitions ultimately required extensive diagnostic testing and documentation. As soon as subjects deprotocol efficacy analysis. Every effort was made to continue to obtain follow-up information on subjects who left areas of veloped symptoms suggestive of possible LD, they were asked to make a site visit for an acute evaluation. This evaluation endemicity, in order to ensure that they had not developed signs or symptoms of LD as a result of the long latency period was based on the medical history, physical examination, WB assays and testing of sera for titers of antibody to OspA, and following potential exposure.
Undoubtedly, one of the factors that helped us achieve our additional testing depending upon the symptomatology. In the event of rash, photographs and skin biopsy specimens (for enrollment goal of ú10,000 subjects in a 2-month period was the anxiety that LD has instilled into the affected communities.
culture and PCR for B. burgdorferi) were obtained in standardized fashion. In many areas, confusion regarding the diagnosis, treatment, and potential sequelae has heightened the fear of contracting Arthrocenteses were performed if clinically indicated. Photographs were also obtained to document facial palsy. Radicu-LD. Although subjects were fully instructed that this was a placebo-controlled trial and that efficacy had yet to be proven, lopathy, syncope, and meningitis or encephalopathy were evaluated and documented with the appropriate laboratory test: this did not dampen the enthusiasm and the willingness of the subjects and, in some cases, of the entire community to nerve conduction studies, electrocardiography, and lumbar puncture, respectively. participate.
Subjects were asked to return to the site 2 -4 weeks later for a follow-up visit to assess their condition and obtain a Case Definition convalescent serum sample for WB testing. In addition, each vaccinee had sera drawn at baseline and Another critical component in any trial is defining the primary endpoint and the case definitions. For most vaccine trials, after both transmission seasons for WB testing to detect seroconversion. The WB specimens at month 12 from all vaccinees a well-defined clinical endpoint is identifiable, usually in the form of culture, serological assay, or recognized clinical signs were collected from February to April and needed to be tested / 9c34$$jy05 06-06-97 21:09:40 cida UC: CID before the busiest time of the second transmission season, when participation in the trial. Since the postcard system was so successful, it was repeated with modifications during the secacute and convalescent serum results for new suspected cases would be awaited anxiously by subjects. Collecting such extenond transmission season. sive data to document a case required a willingness on the part of all the investigators to devote the necessary resources to Suspected LD Cases such an effort. The number of well-documented confirmed cases (Ç1% of the participants after the first transmission seaAll subjects who developed symptoms of LD were asked to return to the investigator's site for further evaluation. This son) is a tribute to their efforts.
In the phase II studies it became evident that a significant evaluation included the obtaining of acute and convalescent serum samples for OspA antibody testing and WB assays. Depercentage of skin lesions clinically thought to represent obvious erythema migrans could not be confirmed with culture, pending upon the symptoms, other specimens (synovial fluid, CSF, skin biopsy) were obtained for culture, PCR, or testing PCR, or determination of seroconversion. Therefore, in the phase III study, all patients with possible erythema migrans for T cell -mediated immunity. All of the testing was performed by one central laboratory rashes -no matter how ''classic'' -had to undergo full diagnostic evaluation. Adequate photographic documentation of the (that of Dr. Allen Steere), and the challenge was to provide the investigator with the results within 48 hours. The coordinating lesions was also important, and careful consideration was given to selection of the photographic guidelines and equipment. Difphysician (Dr. Steere) and the site investigators remained blinded throughout the study since the WBs were interpreted by ferent categories were assigned to those erythema migrans lesions confirmed by laboratory testing vs. those about which the laboratory technicians only. Dr. Steere and the investigators received the test results in blinded fashion, without mention of there was only a strong clinical suspicion.
the presence or absence of a 31-kD (OspA) band.
At the initiation of the study, the concern was that suspected Surveillance cases would not come to the investigator's attention -hence the need for constant surveillance. Early in the first transmisOnce case definitions were determined and an algorithm constructed to obtain the supportive data, the question of sursion season, it became obvious that there was a very high rate of recall among the participants and that the challenge would veillance for the detection of suspected LD cases among ú10,000 vaccinees was addressed. Enrollees were given walbe to process all the specimens in the required time frame. Ultimately, ú10% of the total study population was evaluated let-size cards as well as refrigerator magnets as a reminder of their participation in the study. We believed that a postcard for suspected LD; ú2,500 specimens were submitted to the laboratory for this subpopulation alone. system was most likely to ensure continued participation on the part of the enrollees as well as to capture all the information In addition, the same laboratory was responsible for performing systematic WB testing on each vaccinee as previously needed to identify potential cases that might not otherwise be available.
described. Collecting data on these subjects, processing their specimens, notifying sites of the results, and entering the inforPostcards were sent to each vaccinee five times during the first transmission season of the trial. Each postcard listed a mation into the database became a monumental task. All of this was a direct result of our desire to apply a very high level series of questions regarding the appearance of potential LD symptoms and other significant health problems. If any sympof suspicion in order to capture all the suspected cases and to accurately identify and categorize documented cases of LD. tom was checked off, the site contacted the subject for additional information and arranged a visit, if necessary. The subjects always had the option of contacting the investigator Data Management regarding their symptoms.
More than 54,000 postcards were mailed to enrollees, and Conducting a trial of this magnitude required that both the sponsor and the sites, especially those with enrollments of an impressive 90% were returned to the sites. An additional 7% of enrollees provided information when contacted by tele-900 and 1,200 enrollees, be prepared to deal with the tremendous volume of data. Since it would have been impractical phone. Only 3% of the postcard data were not retrieved, which again serves as witness to the outstanding compliance of the to have paper case-report forms filled out and manually entered into a database, an electronic remote data-entry system study participants.
At the end of the first transmission season, after all the was used. Although additional up-front time was required to design screens and arrange training for site and sponsor suspected cases had been identified, the sites were surveyed to determine the number of suspected cases identified specifically personnel, the on-site computer system appears to be a worthwhile investment. through the postcard system. Fewer than 1% of the suspected cases were identified via this mechanism, a finding confirming Another major benefit is access to the data in ''real time,'' allowing up-to-date safety surveillance. The number of adverse the efficiency of the surveillance system. Undoubtedly, the postcards served as a constant reminder to the enrollees of their events collected for ú10,000 subjects followed for 2 years also / 9c34$$jy05 06-06-97 21:09:40 cida UC: CID
